☆ 4.6 Article

Rapid bacteriolysis of Staphylococcus aureus by lysin exebacase

MICROBIOLOGY SPECTRUM (2023)

Related references

Note: Only part of the references are listed.

Article Microbiology

Exploration of Bacterial Re-Growth as In Vitro Phenomenon Affecting Methods for Analysis of the Antimicrobial Activity of Chimeric Bacteriophage Endolysins

Ursula Kaspar et al.

Summary: Recombinant bacteriophage endolysins PRF-119 and its successor HY-133 have been found to be highly active against various MRSA clonal lineages. However, in vitro re-growth phenomenon was observed, necessitating clarification for the assessment of the agent's stability and activity as well as for methodological aspects of endolysin testing. Factors such as the shape and material of culture vessels and shaking conditions were identified to influence the in vitro stability and activity of HY-133. The findings provide a basis for future standardization and accurate determination of the antimicrobial activities of engineered endolysins.

MICROORGANISMS (2022)

Add to Collection

Review Microbiology

Direct Lytic Agents: Novel, Rapidly Acting Potential Antimicrobial Treatment Modalities for Systemic Use in the Era of Rising Antibiotic Resistance

Raymond Schuch et al.

Summary: Direct lytic agents (DLAs) are novel antimicrobial compounds that rapidly destabilize cell walls and kill bacteria. They can complement and synergize with traditional antibiotics without causing resistance to DLAs. DLAs have potent bactericidal activity against multidrug-resistant Gram-negative pathogens, and their activity is maintained in biological matrices. This makes them promising candidates for the treatment of life-threatening invasive infections.

FRONTIERS IN MICROBIOLOGY (2022)

Add to Collection

Article Infectious Diseases

Locally delivered antistaphylococcal lysin exebacase or CF-296 is active inmethicillin-resistant Staphylococcus aureus implant-associated osteomyelitis

Melissa Karau et al.

Summary: The study demonstrates that local delivery of exebacase or CF-296 can be an effective complement to conventional antibiotics for the treatment of implant-associated infections.

JOURNAL OF BONE AND JOINT INFECTION (2022)

Add to Collection

Article Microbiology

Development of a Broth Microdilution Method for Exebacase Susceptibility Testing

Jun T. Oh et al.

Summary: Exebacase, a novel lysin with antistaphylococcal activity, is in phase 3 of clinical development. A modified broth microdilution method using CAMHB-HSD was developed to determine exebacase susceptibility. Preliminary QC ranges have been validated to generate accurate MIC data.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Immunology

1059. In vitro Activity of Exebacase (CF-301) against Staphylococcus aureus Causing Bacteremia in the United States, Including Multidrug-resistant Subsets

Rodrigo E Mendes et al.

Open Forum Infectious Diseases (2021)

Add to Collection

Review Virology

The Advantages and Challenges of Using Endolysins in a Clinical Setting

Ellen Murray et al.

Summary: Antibiotic-resistant pathogens are on the rise, posing a growing problem. Traditional antibiotics are no longer effective, creating a need for new approaches. Bacteriophage-derived proteins, such as endolysins, have shown promise in effectively targeting and destroying bacterial cells, particularly Gram-positive bacteria. This has led to a renewed interest in endolysin therapy and its potential as a new antimicrobial therapy, despite some regulatory and logistical challenges.

VIRUSES-BASEL (2021)

Add to Collection

Article Microbiology

Exebacase in Addition to Daptomycin against MRSA

Razieh Kebriaei et al.

Summary: Exebacase is a lysin that shows lytic activity against Staphylococcus aureus, including MRSA. Time-kill analysis experiments demonstrate the bactericidal activity of exebacase-daptomycin combination against MRSA strains. Additionally, in an ex vivo pharmacokinetic/pharmacodynamic simulated model, exebacase in combination with daptomycin reduces CFU/g counts of MRSA strain MW2 effectively.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Exebacase Demonstrates In Vitro Synergy with a Broad Range of Antibiotics against both Methicillin-Resistant and Methicillin-Susceptible Staphylococcus aureus

Aubrey Watson et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)

Add to Collection

Article Microbiology

The Antistaphylococcal Lysin, CF-301, Activates Key Host Factors in Human Blood To Potentiate Methicillin-Resistant Staphylococcus aureus Bacteriolysis

Chiara Indiani et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Microbiology

Postantibiotic and Sub-MIC Effects of Exebacase (Lysin CF-301) Enhance Antimicrobial Activity against Staphylococcus aureus

Jun Taek Oh et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Article Multidisciplinary Sciences

Structural bases of peptidoglycan recognition by lysostaphin SH3b domain

Pawel Mitkowski et al.

SCIENTIFIC REPORTS (2019)

Add to Collection

Article Multidisciplinary Sciences

Determining bacteriophage endopeptidase activity using either fluorophore-quencher labeled peptides combined with liquid chromatography-mass spectrometry (LC-MS) or Forster resonance energy transfer (FRET) assays

Rolf Lood et al.

PLOS ONE (2017)

Add to Collection

Article Microbiology

Bacteriophage Lysin CF-301, a Potent Antistaphylococcal Biofilm Agent

Raymond Schuch et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Article Microbiology

Draft Genome Sequence of Methicillin-Sensitive Staphylococcus aureus ATCC 29213

Isha Soni et al.

GENOME ANNOUNCEMENTS (2015)

Add to Collection

Article Immunology

Combination Therapy With Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia

Raymond Schuch et al.

JOURNAL OF INFECTIOUS DISEASES (2014)

Add to Collection

Article Microbiology

Novel Bacteriophage Lysin with Broad Lytic Activity Protects against Mixed Infection by Streptococcus pyogenes and Methicillin-Resistant Staphylococcus aureus

Daniel B. Gilmer et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)

Add to Collection

Article Infectious Diseases

Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium

Geoffrey A. McKay et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)

Add to Collection

Article Microbiology

Genome sequence of Staphylococcus aureus strain newman and comparative analysis of staphylococcal genomes: Polymorphism and evolution of two major pathogenicity islands

Tadashi Baba et al.

JOURNAL OF BACTERIOLOGY (2008)

Add to Collection

Article Biochemistry & Molecular Biology

Cell wall-targeting domain of glycylglycine endopeptidase distinguishes among peptidoglycan cross-bridges

JZQ Lu et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Add to Collection

Article Multidisciplinary Sciences

A bacteriolytic agent that detects and kills Bacillus anthracis

R Schuch et al.

NATURE (2002)

Add to Collection

Article Multidisciplinary Sciences

Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme

D Nelson et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.